Armistice Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Armistice Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-130,000	Closed	-$59.6M	–	441
2025 Q3	$59.6M	Sell	130,000 -40,000	-24%	-$14.9M	0.88%	15
2025 Q2	$51.4M	Sell	170,000 -130,000	-43%	-$38.7M	0.89%	12
2025 Q1	$99.4M	Buy	+300,000	New	+$98.6M	1.49%	9
2024 Q1	–	Sell	-280,000	Closed	-$64.8M	–	383
2023 Q4	$64.8M	Buy	280,000 +120,000	+75%	+$21M	0.88%	20
2023 Q3	$23.4M	Buy	+160,000	New	+$30.1M	0.36%	51
2023 Q2	–	Sell	-125,000	Closed	-$30.3M	–	255
2023 Q1	$30.3M	Buy	+125,000	New	+$34.1M	0.44%	48

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital's MDGL Position: Q2 2026 in Review

Armistice Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 8.9% in Q2 2026, buying an estimated $12M and bringing the position to 288,000 shares worth $155M. The position accounts for 1.89% of the portfolio, ranked #3.

Armistice Capital first reported a position in MDGL in Q1 2015 and has held it in 41 quarters since. The position peaked at $155M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Armistice Capital held 288,000 shares of Madrigal Pharmaceuticals worth $155M as of Q2 2026.
Armistice Capital bought 23,417 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $12M.
Madrigal Pharmaceuticals made up 1.89% of Armistice Capital's portfolio in Q2 2026, its #3 holding.
Armistice Capital first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 41 quarters since.
Armistice Capital's Madrigal Pharmaceuticals position peaked at $155M in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.